A HUMANIZED ANTIBODY SPECIFIC FOR THE PLATELET INTEGRIN GPIIB/IIIA

被引：0

作者：

CO, MS ^{[1
]}

YANO, S ^{[1
]}

HSU, RK ^{[1
]}

LANDOLFI, NF ^{[1
]}

VASQUEZ, M ^{[1
]}

COLE, M ^{[1
]}

TSO, JT ^{[1
]}

BRINGMAN, T ^{[1
]}

LAIRD, W ^{[1
]}

HUDSON, D ^{[1
]}

KAWAMURA, K ^{[1
]}

SUZUKI, K ^{[1
]}

FURUICHI, K ^{[1
]}

QUEEN, C ^{[1
]}

MASUHO, Y ^{[1
]}

机构：

[1] YAMANOUCHI PHARMACEUT CO LTD,YAMANOUCHI INST MOLEC MED,TOKYO,TOKYO,JAPAN

来源：

JOURNAL OF IMMUNOLOGY | 1994年 / 152卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

C4G1, a murine mAb reactive with the platelet gpIIb/IIIa integrin, was humanized for potential treatment of thrombosis-related disorders. The variable regions of light- and heavy-chain cDNAs from the C4G1 hybridoma were first cloned and sequenced. Humanized C4G1 Ab of the IgG1 isotype was constructed by combining the complementarity-determining regions of C4G1 with human framework and constant regions. The human framework was chosen to maximize homology with the C4G1 variable region sequence, and a computer model of C4G1 was used to aid design of the final framework sequence. Genetic constructs were also developed to produce Fab and F(ab')(2) fragments of the humanized C4G1 Ab. The humanized IgG1 Ab as well as the Fab and F(ab')(2) fragments showed equivalent binding affinities to their murine counterparts, indicating no loss in binding affinity during the humanization process. The humanized Ab and its fragments were also shown to inhibit platelet aggregation and to inhibit binding of fibrinogen to gpIIb/IIIa in vitro.

引用

页码：2968 / 2976

页数：9

共 50 条

[21] Effects of platelet GPIIb/IIIa antibody and antibody-urokinase conjugate adsorbed to stents on platelet deposition and neointima formation
Aggarwal, RK
Martin, WA
Azrin, MA
Ezekowitz, MD
deBono, DP
Gershlick, AH
CIRCULATION, 1996, 94 (08) : 1510 - 1510
[22] LIGANDS ACTIVATE INTEGRIN ALPHA-IIB-BETA-3 (PLATELET GPIIB-IIIA)
DU, XP
PLOW, EF
FRELINGER, AL
OTOOLE, TE
LOFTUS, JC
GINSBERG, MH
CELL, 1991, 65 (03) : 409 - 416
[23] A novel regulatory epitope defined by a murine monoclonal antibody to the platelet GPIIb-IIIa complex (alpha IIb beta 3 integrin)
Tokuhira, M
Handa, M
Kamata, T
Oda, A
Katayama, M
Tomiyama, Y
Murata, M
Kawai, Y
Watanabe, K
Ikeda, Y
THROMBOSIS AND HAEMOSTASIS, 1996, 76 (06) : 1038 - 1046
[24] Acute systemic reaction and lung alterations induced by an antiplatelet integrin gpIIb IIIa antibody in mice
Nieswandt, B
Echtenacher, B
Wachs, FP
Schröder, J
Gessner, JE
Schmidt, RE
Grau, GE
Männel, DN
BLOOD, 1999, 94 (02) : 684 - 693
[25] Evaluation of an antibody-based genotype classification of the platelet fibrinogen receptor (GPIIb/IIIa)
Schwippert-Houtermans, B
Strapatsakis, S
Roesen, P
Tschoepe, D
CYTOMETRY, 2001, 46 (04): : 238 - 242
[26] Inhibitors of GPIIb/IIIa platelet receptors.
Chanu, B
ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 1999, 92 (07): : 893 - 902
[27] Staphylococcus aureus iron regulated surface protein (ISDB) directly binds to platelet integrin gpiib/IIIa
Zapotoczna, M. A.
Foster, T. J.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 65 - 65
[28] CALCIUM AND TEMPERATURE REGULATION OF THE STABILITY OF THE HUMAN PLATELET INTEGRIN GPIIB/IIIA IN SOLUTION - AN ANALYTICAL ULTRACENTRIFUGATION STUDY
RIVAS, GA
USOBIAGA, P
GONZALEZRODRIGUEZ, J
EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, 1991, 20 (05): : 287 - 292
[29] High resolution functional AFM Imaging of fibrinogen and platelet integrin GPIIb/IIIa at solid/liquid interfaces
Siedlecki, CA
Hussain, MA
Agnihotri, A
CIRCULATION, 2003, 108 (17) : 30 - 30
[30] Genetic variation in platelet integrin αIIbβ3 (GPIIb/IIIa) and the metastatic potential of renal cell carcinoma
Kallio, Jukka P.
Mikkelsson, Jussi
Tammela, Teuvo L. J.
Karhunen, Pekka J.
Kellokumpu-Lehtinen, Pirkko
BJU INTERNATIONAL, 2006, 98 (01) : 201 - 204

← 1 2 3 4 5 →